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AbstrAct:
Previous genetic analyses have suggested that mutations of the genes encoding 
PI3Kα  facilitate  invasion  and  metastasis  but  have  less  effect  on  primary  tumor 
growth.    These  findings  have  major  implications  for  therapeutics  but  have  not 
been  factored  into  pre-clinical  drug  development  designs.    Here  we  show  that 
the  inhibition  of  PI3Kα  by  newly  designed  small  molecule  inhibitors  prevented 
metastasis formation in mice but had much less effect on the growth of subcutaneous 
xenografts or primary intra-abdominal tumors. These data support the idea that 
PI3Kα plays an important role in the metastatic process and suggest a more informed 
strategy for selecting drugs worthy of further development for clinical application.
INtrODUctION
The phosphatidylinositol-3-kinases (PI3K) class 
1A family is a critical regulator of growth, motility and 
survival functions [1]. PI3K class 1A members transmit 
signals from a variety of growth factor receptors, creating 
phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 
serves as activator and membrane docking station for 
PDK1 and Akt proteins, thereby initiating a kinase 
cascade that connects the cell membrane receptors with 
nuclear transcription factors. In light of its central role 
in numerous cellular processes, the phosphorylation of 
phosphatidylinositol 4,5-bisphosphate (PIP2) is tightly 
regulated, with PTEN reversing the phosphorylation of 
PIP2 catalyzed by PI3K Class 1A family members. 
The alpha isoform of PI3K (PI3Kα) is one of the 
most frequently mutated kinases in solid tumors [2, 3]. 
Structural insights from the study of normal and mutated 
forms of PI3Kα suggest a release of inhibition by its 
regulating subunit p85 as well as altered membrane 
binding as causes for the observed biochemical over 
activity of the mutants [4-8]. The mutational activation 
of PI3Kα permits cell survival in culture when growth 
factors are limiting [6, 8]. 
PI3Kα  is  a  heterodimer  of  a  catalytic  subunit 
encoded by PIK3CA and one of several regulatory 
subunits [9]. The high frequency of PIK3CA mutations in 
human tumors, the localization of mutations to particular 
“hotspot” regions, and the enhanced enzymatic activity of 
the mutant gene’s products have made PI3Kα a preferred 
target for drug development. Indeed, PI3KCA is one of the 
two most highly mutated oncogenes ever discovered (the 
other being KRAS). For these reasons, many academic 
and industrial groups are attempting to develop inhibitors 
of this enzyme [10-21]. There are currently nine PI3K 
inhibitors in clinical trials, none of which are particularly Oncotarget 2010; 1:  339 - 348 340 www.impactjournals.com/oncotarget
specific for PI3Kα. These inhibitors can be classified into 
six core structures. PX-866 and SF1126 are analogues of 
wortmannin and LY294002, respectively, with improved 
pharmacokinetic properties [13, 22]. NVP-BEZ235, PF-
04691502, BGT226 and XL765 are novel compounds 
with  a  broader  and  more  potent  inhibition  profile  that 
target PI3Ks as well as mTOR [23-25]. GDC-0941, 
XL147 and NVP-BKM120 are potent pan PI3K class 1A 
inhibitors lacking mTOR inhibition [26, 27].
Metastases, rather than the primary tumors 
themselves, are the cause of death in the vast majority of 
cancer patients. Interestingly, cancer cell lines in which the 
spontaneously mutated PI3Kα is genetically disrupted still 
grow as xenografts in nude mice, though their metastatic 
ability is severely compromised [8]. Similarly, cell lines 
in which Akt1 and Akt2 are genetically disrupted form 
xenografts at their primary sites but do not metastasize 
as well as their parental lines [28]. Overexpression of 
Akt1 has also been shown to enhance metastasis in rodent 
models and Akt2 knockdown inhibited such metastasis 
[29]. Clinical evidence of the importance of the PI3K/
Akt pathway in metastasis development has also been 
documented [30, 31]. 
The purposes of the current study were (i) to 
introduce a novel set of PI3Kα specific inhibitor analogs 
based on an imidazopyridine core, and (ii) to test the most 
promising of these compounds for their in vivo activities 
against primary and metastatic tumors.
rEsULts
synthesis and structure–activity relationship 
(sAr) studies of imidazopyridine-based J-series 
compounds 
We synthesized 121 compounds based on N’- [(1E)-
(6-Bromoimidazo [1,2-a]pyridin-3-yl)methylene]-N,2-
dimethyl-5-nitrobenzenesulfonohydrazide hydrochloride 
(J27),  a  potent  PI3Kα  inhibitor  reported  previously 
[14]. Cyclization of 5-bromo-2-aminopyridine with 
chloroacetaldehyde gave imidazopyridine, which was 
formylated and further reacted with various hydrazines 
to provide the key intermediate compound 3. Acylation 
or sulfonylation of compound 3 generated the desired 
compounds (Supplementary scheme 1). Each of the 
compounds was tested for selective biochemical inhibition 
of PI3K isoforms in vitro. For this purpose, a baculovirus-
based expression system was used to produce the catalytic 
and regulatory subunits of PI3Kα, PI3Kβ, and PI3Kδ. In 
the case of PI3Kγ, no regulatory subunit was required for 
activity [32]. 
SAR studies began by changing R1 from methyl (J27) 
to ethyl (J32). The potency for PI3Kα was retained but 
selectivity against the other three isoforms increased by up 
to 8-fold (Supplementary scheme 1, Table 1). Increasing 
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Figure 1: biochemical activities of selected J-series compounds exemplify their PI3Kα selectivity and potency. Inhibitor 
concentration is plotted against relative biochemical activity. Four PI3K isoforms were tested: alpha (red), beta (blue), gamma (green) and delta 
(purple). The structures of the compounds are shown above each panel.Oncotarget 2010; 1:  339 - 348 www.impactjournals.com/oncotarget 341
table 1 | structure activity relationship of J-series compounds
N
N
Br
H
N N
R1
X
R2
R3
R4
Structure IC50 [μM]
No R1 R2 R3 R4 X p110α p110β p110γ p110δ
J27 CH3 CH3 NO2 H SO2 0.017 0.140 0.075 0.423
J30
*
CH3 NO2 H SO2 0.730 6.311 3.159 0.781
J32 Et CH3 NO2 H SO2 0.015 1.200 0.620 1.400
J37 Et H NO2 H SO2 0.055 3.061 0.801 0.476
J40 Et CH3 H H SO2 20.00 61.00 180.00 53.00
J41 Et CH3 * S
O
O
H SO2 23.23 235.2 253.40 3.553
J43
*
O
O
CH3 NO2 H SO2 0.154 1.899 0.930 0.363
J44 Et CH3 NH2 H SO2 4.400 21.00 30.00 28.00
J45 Et CH3 NO2 H CO 0.020 0.075 0.132 0.016
J46
*
CH3 NO2 H SO2 0.309 2.971 1.753 0.485
J47
*
N
CH3 NO2 H SO2 0.025 0.149 0.192 0.169
J55
*
CH3 NO2 H SO2 0.093 2.417 3.343 0.760
J100 Et CH3 COOH H SO2 0.121 1.999 5.124 0.173
J101 Et Cl NO2 H SO2 0.022 0.936 0.812 0.266
J120 Et CH3 NO2 F SO2 0.024 1.900 1.800 0.470
J124 Et CH3 NO2
*
N H
O
F
F
F SO2 0.011 0.270 0.380 0.160
J124-I Et CH3 NO2 NH2 SO2 0.002 0.046 0.073 0.026
J125 Et Cl
*
O NH2
H SO2 0.076 0.600 1.000 0.038
J128 Et Cl NO2 NH2 SO2 0.004 0.130 0.250 0.110
J129 Et CH3 NO2 OH SO2 0.020 0.510 0.150 0.066
J157 Et CH3 NO2
*
N H
O SO2 0.024 3.000 1.000 0.430Oncotarget 2010; 1:  339 - 348 www.impactjournals.com/oncotarget 342
J158 Et CH3 NO2
*
N H
O
O H
SO2 0.017 3.500 0.200 0.440
J159 Et CH3 NO2
*
N H
OH
O
SO2 0.004 1.878 0.032 0.348
J160 Et CH3 NO2
*
N H
OH
O
SO2 0.011 8.200 0.140 0.230
J161 Et CH3 NO2
*
N H
O
O
SO2 0.033 1600 0.940 16.00
J162 Et CH3 NO2
*
N H
OH
SO2 0.025 2.400 0.210 0.400
J163 Et CH3 NO2
*
N H
NH2
O
SO2 0.014 2.100 0.074 0.130
J171 Et CH3 NO2
*
N H
N
H
O
O OH
SO2 0.019 12.76 1.151 1.958
table 1: structure-activity relationship table of representative J-series compounds.  Representative compounds along with 
enzymatic potencies are listed. 
the size of R1 by substituting ethyl (J32) with isopropyl 
(J55), iso-butyl (J46) or benzyl (J30) caused a 6 to 49-
fold drop in inhibitory activity for PI3Kα. Polar groups 
such as ester (J43) and nitrile (J47) at R1 did not increase 
potency. A switch of the sulfonyl group at X to a carbonyl 
(J45) did improve inhibitory activity for PI3Kβ, PI3Kγ 
and PI3Kδ, but not for PI3Kα, thus decreased selectivity 
for the latter. With respect to the terminal phenyl ring, 
deleting a methyl group at R2 (J37) or a nitro group at 
R3 (J40) resulted in greater than 3.6-fold and 1333-fold 
decreases in inhibitory activity for PI3Kα, respectively. 
However, a chloro (J101) substituent at R2 was able to 
maintain potency and isoform selectivity as long as a nitro 
group was also present at R3. The R3 nitro group turned 
out to be critical in this configuration, as substitutions by 
various moieties, including carboxylic acid (J100), amino 
(J44), amido (J125) and methyl sulfonyl (J41) groups all 
impaired potency. We discovered that a substitution at 
the R4 position next to the nitro group on the phenyl ring 
was beneficial and that the R4 position in general accepted 
larger substituents without major impact on potency. 
Amino (J124-I), glycino (J159) and trifluoroacetylamino 
(J124) groups at the R4 position increased inhibitory 
activity for PI3Kα by 7.5, 3.8 and 1.4-fold, respectively, 
when compared to J32. Other substitutions, such as fluoro 
(J120), hydroxyl (J129) and various amino groups (J157, 
J158, J161, J162, J163), did not impact the inhibitory 
activity for PI3Kα substantially. Even larger substitutions 
as well as oligopeptide adducts retained nanomolar 
potencies (e.g. J171). 
In summary, seventy-four of the 121 compounds 
had a IC50 for PI3Kα below 1 µM, but of these, only 42 
had IC50’s below 100 nM and 9 had IC50’s below 20 nM 
(examples in Fig. 1). The most specific of these (J171) 
had ~670-fold selectivity against PI3Kβ, 60-fold against 
PI3Kγ, and 100-fold against PI3Kδ with a potency of 19 
nM for PI3Kα (Table 1). More typical selectivity values 
were >20 (β), >30 (γ), and >10 (δ), respectively, with a 
potency for PI3Kα at 10 nM (e.g. J124). The compounds 
were also tested for their capacity to inhibit two common 
mutant forms of PI3Kα – E545K and H1047R [2, 33]. 
None of the compounds discriminated between the wild-
type (wt) and mutant forms of the enzyme (data not 
shown). Finally, we also tested one of the compounds 
(J124, chosen for reasons discussed later) against a panel 
of 273 kinases. This compound proved to be moderately 
selective, inhibiting 22 of 273 tested kinases, but not 
mTOR, with an IC50 of 11 nM or lower (Supplementary 
Table 1). 
J-series compounds inhibit the proliferation of 
cancer cells with and without mutant PI3Kα 
All  42  compounds  with  a  PI3Kα  IC50 below 100 
nM were assayed for their ability to inhibit the growth of 
HCT116 cells in culture. These cells were derived from a 
human colorectal cancer containing one mutant (H1047R) 
and one normal allele of the PIK3CA gene. Paired isogenic 
lines in which one of the two alleles was disrupted through 
homologous recombination have been generated [8] and 
were also tested. We found that the 42 compounds inhibited 
cell growth to varying extents, but none of them inhibited 
the growth of the cells with a mutant PIK3CA allele more Oncotarget 2010; 1:  339 - 348 343 www.impactjournals.com/oncotarget
than their isogenic counterparts with only a normal allele 
(example in Fig. 2A). It has previously been demonstrated 
that the PIK3CA mutations allow cells to proliferate in 
growth medium containing limiting concentrations of 
growth factors [2]. Cells with both genotypes were more 
sensitive to the compounds when grown under conditions 
where growth factors were limiting, but these conditions 
did  not  provide  specificity  for  the  cells  with  a  mutant 
PIK3CA allele (Fig. 2A) 
To identify the most promising drug leads for in 
vivo evaluation, a matrix of cellular and biochemical 
potency of the 42 compounds with nanomolar IC50’s was 
constructed (Fig. 2B). We searched for potent compounds 
that inhibited cell growth at concentrations consistent with 
their ability to inhibit PI3Kα enzymatic activity. None of 
the compounds inhibited growth at concentrations less 
than their biochemical Ki. Compounds that did not inhibit 
cell growth even at concentrations much greater than their 
Ki’s were assumed to be cell impenetrant or inactive in 
an intracellular environment. Four compounds (J32, J124, 
J124-I, and J128) with biochemical and cellular activities 
which we considered optimal were chosen for further 
analysis. 
To determine whether these compounds inhibited 
the  pathway  regulated  by  PI3Kα,  we  evaluated  the 
phosphorylation of Akt1 and Akt2 in HCT116 cells 
following exposure to the compounds for 6 hours. Previous 
studies have demonstrated that the Akt1 and Akt2 proteins 
are reliable indicators of PI3Kα pathway activity [8, 28]. 
As assessed by western blot, the four compounds all 
inhibited phosphorylation of Akt1 and Akt2 when used at 
concentrations that inhibited cell growth (example in Fig. 
2C).
J-series compounds are potent and selective 
inhibitors of metastatic disease
We next tested these compounds in vivo. Through 
Figure 2: cellular activity of J-series compounds. (a), Efficacy of J124 in parental and isogenic HCT116  lines harboring wild-type 
or mutated PIK3CA alleles. (b), Activity matrix of cellular versus biochemical potency. Only J-series compounds with IC50 below 100 nM 
are shown. Compounds with no apparent cellular activity were assigned the default EC50 value of 1 mM. (c), Western blots demonstrating 
inhibitory effect of J124-I compound on phosphorylation of downstream effector Akt in HCT116 cells. (d), Intra-tumor P-Akt levels in 
HCT116 xenografts  are reduced up to 3 hours post J124-I IP injection . Oncotarget 2010; 1:  339 - 348 344 www.impactjournals.com/oncotarget
dose escalation studies, we found that the compounds 
were tolerated at concentrations up to 150 mg/kg when 
administered intraperitoneally daily for three weeks. Two 
of the compounds (J32, J124-I) were evaluated for their 
ability to inhibit the growth of subcutaneous HCT116 
xenograft tumors in nude mice. Only a minor anti-tumor 
activity was noted (Supplementary Fig. 1), even though 
the compound inhibited the phosphorylation of Akt1/2 in 
the growing tumors (Fig. 2D). 
To test the compounds in a context more relevant 
to the proposed tumorigenic role of PI3Kα, we evaluated 
their ability to inhibit the development of metastases from 
tumors injected into the spleen. Such injections give rise to 
large, primary intrasplenic tumors and multiple metastatic 
lesions in the liver, as well as a few tumor nodules in the 
lungs. The tumor-bearing animals were treated daily by 
intraperitoneal injections of J124 or J128 at 150 mg/kg 
starting three days after tumor implantation. Metastatic 
Figure 3: J124 and J128 have anti-metastatic efficacy in a metastasis model. (a), Livers of mice treated with J124 and J128 as 
opposed to vehicle alone show distinctive difference in the number of tumor nodules. (b), Representative liver H&E sections of treated and 
untreated animals underscore differential liver metastasis load. Arrows indicate tumor lesions, bar length 200 μm. (c), Relative amount of 
tumor DNA in organs of treated and untreated animals. LINE-qPCR confirmed the reduced metastatic burden in livers of animals treated with 
J124 or J128. Oncotarget 2010; 1:  339 - 348 345 www.impactjournals.com/oncotarget
burdens were assessed through histopathology analysis 
three weeks later. All mice had large intrasplenic tumors, 
but the mice injected with J124 or J128 had few, if any, 
metastatic foci in their livers compared to animals injected 
with the vehicle alone (Fig. 3A). Sections of the liver and 
lungs revealed multiple tumor foci in control mice but not 
in mice treated with J124 or J128 (Fig. 3B).
To quantitatively measure metastatic tumor burdens 
in these mice, we performed real-time PCR using human-
specific  primers  [34].  The  spleens  of  the  mice  treated 
with J124 or J128 showed a modest reduction in primary 
tumor burdens (~50%) compared to the mice treated with 
only the vehicle (Fig. 3C). In contrast, the metastatic liver 
burden was reduced by 13-fold and 9-fold, respectively, 
in the mice treated with J124 and J128. There were a few 
metastatic lesions in the lungs of the control mice but no 
lesions in the lungs of the treated mice. 
DIscUssION
We describe above a class of inhibitors that are 
highly specific for the alpha isoform of PI3K enzymes. 
Most published cell biologic and physiologic studies 
employing PI3Kα inhibitors have used either wortmannin 
or LY290042. These classic compounds have proven 
useful but are non-specific with respect to PI3K isoforms. 
The compounds we have synthesized should prove 
superior for such research purposes and will be made 
freely available upon request. Furthermore, the detailed 
evaluation of structure activity relationships provides 
leads for further optimization of this and related classes 
of compounds. Particularly intriguing was the discovery 
that the R4 position accepted very large substituents, 
even peptides, without major impact on potency. This 
finding sets the stage for the development of bi-functional 
compounds that may have uniquely specific activities. 
Our studies also provide strong pharmacologic 
evidence for the role of PI3Kα in metastasis. Apart from 
the biologic implications of this finding, it has important 
practical  ramifications.  All  anti-cancer  compounds, 
including those targeting PI3Kα, are tested in pre-clinical 
models prior to their introduction into Phase I clinical 
trials. In general, therapeutic efficacy against a well-chosen 
tumor cell line is required to move forward. For example, 
PI3Kα inhibitors might be tested against xenografts of 
human cancer cell lines which have mutations of PIK3CA, 
for obvious reasons. Our results show that it is not only 
the choice of cell line that is important for pre-clinical 
testing, but also the choice of the in vivo model in which 
the testing is performed. J124 and J128 have little activity 
against subcutaneous tumors, or even against intra-
abdominal primary tumors, but could potently inhibit 
the development of metastases. These results suggest 
that testing of novel compounds against tumors grown 
subcutaneously in immunocompromised mice could be 
misleading, stimulating researchers to discard drugs that 
might be useful in the clinic. 
The pharmacologic data provided in this study are 
in perfect accord with prior genetic data. In particular, 
homologous recombination-mediated disruption of a 
mutant PIK3CA allele did not inhibit the growth of primary 
tumors but did inhibit metastatic growth [8]. No drug could 
possibly inhibit the mutant PI3Kα isoform as completely, 
permanently,  and  specifically  as  a  genetic  knock-out. 
We would thus argue that any drug that is designed to 
inhibit this enzyme should yield similar results in vivo, 
exhibiting minor effects on primary tumors and major 
effects on metastases. And conversely, drugs that inhibit 
the growth of primary tumors grown subcutaneously must 
be doing so by off-target effects. We believe that most 
of the drugs now being considered or used for clinical 
trials have not met this straight-forward expectation. On 
a positive note, attention to this expectation could lead to 
an improved selection of drugs for future clinical trials, 
thereby expediting the drug development process.
MAtErIALs AND MEtHODs
chemical compound synthesis
The full synthetic scheme and methods are described 
in Supplementary Scheme 1 and Supplementary Methods.
PI3K expression and purification
cDNA clones of PIK3CA, PIK3CB and PIK3CG were 
obtained from Origene (Rockville, MD, USA). PIK3CD 
was generously provided by Novartis Pharmaceuticals. 
The cDNA clones were sub-cloned into pFastBac His-Tag 
(Invitrogen, Carlsbad, CA, USA) and baculovirus clones 
were generated by the Bac-to-Bac expression system 
(Invitrogen). p110α, p110β and p110δ were co-expressed 
in Sf9 insect cells (Invitrogen) with a nSH2-iSH2 fragment 
of the regulatory subunit p85 comprising AA residues 322 
to  600  [4].  p110γ  was  expressed  without  a  regulatory 
subunit. Sf9 cells were lysed in a buffer containing 50 mM 
sodium phosphate, pH 8.0, 400 mM NaCl, 5% glycerol, 
1% Triton X-100, 10 mM 2-mercaptoethanol, 1 mM 
orthovanadate, 10 mM imidazole, and sonicated on ice 
for 1 minute. Proteins were purified by adding Ni-NTA 
Superflow  beads  (Qiagen,  Valencia,  CA,  USA)  to  the 
lysate and subsequent rolling for 30 min at 4oC. Beads 
were washed twice with 50 mM phosphate buffer, pH 8.0, 
0.5 M NaCl, 50 mM Imidazole, 2 mM DTT and eluted 
in the same buffer but with 200 mM imidazole. Purified 
PI3K’s were mixed 1:1 with glycerol and stored at -20oC.
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biochemical PI3K inhibition assay
J-series inhibitors were dissolved, serial diluted in 
DMSO and deposited into 96 well plates at a final DMSO 
concentration of 1%. We used a novel assay to determine 
their potency and selectivity. In brief, micelles of 2.5 
µg  L-a-Phosphatidylinositol  and  2.5  µg  1,2-Diacyl-sn-
glycero-3-phospho-L-serine were formed by sonication, 
mixed with the individual PI3K isoforms and added to 
the drug dilutions in a reaction buffer containing 10 mM 
HEPES,  25  mM  NaCl,  0.125  µg/µl  BSA,  and  2  mM 
BME (final concentrations). Reactions were timed after 
the addition of 10 µM ATP with 40 μCi/ml γ-32P-ATP 
(PerkinElmer, Waltham, MA, USA) and 2 mM MgCl2 
(all final concentrations). The reactions were terminated 
after two hours by the addition of 2 N HCl and the lipids 
extracted with 1:1 MetOH/Chloroform. Radio-labeled 
phosphatidyl-inositol-3-phosphate in the extracted organic 
fraction was quantified after the addition of Microscint O 
(PerkinElmer) using a TopCount 96 well plate scintillation 
counter (PerkinElmer). IC50 concentrations and inhibition 
curves were calculated using Prism 5 (GraphPad Software, 
La Jolla, CA).
cell-based inhibition assays
The colorectal cancer cell line HCT116 was obtained 
from ATCC and the generation of somatic knock-out 
derivatives with PI3Kα wt or H1047R genotypes has been 
described [8]. Cells were seeded in McCoy’s 5A medium 
(Invitrogen)supplemented with 10% Fetal Bovine Serum 
(FBS, HyClone, Logan, UT, USA)at a density of 4000 
cells per well in 96-well tissue culture plates (Corning, 
Corning, NY, USA). Once the cells had adhered to the 
plates (~5 hours after seeding), J-series inhibitors were 
added. All control and assay wells were adjusted to a final 
DMSO concentration of 1% and incubated for 48 hours. 
The media was removed and the adherent cells lysed by 
incubation for 1 hour at 37oC with 100 µl 10 mM Tris-
HCl, pH 8.8, 0.5% Igepal (Sigma-Aldrich, St. Louis, MO, 
USA), 25 µg/ml Proteinase K (Invitrogen), and 0.05% 
SYBR green (Applied Biosystems, Carlsbad, CA, USA). 
DNA was measured with a FLUOstar Galaxy 96-well 
plate reader (BMG Labtech, Cary, NC, USA), and cell 
numbers were approximated by DNA content. 
P-Akt western analysis
Phopspho-Akt levels were assayed in HCT116 
cells. 1x106 cells/well were seeded in six-well plates 
and serum starved for 2 hours in McCoy’s 5A medium. 
Drugs were pre-mixed with complete medium containing 
10% FBS and incubated with the cells for 6 hours. Cells 
were lysed on ice with 100 mM Tris-HCl, pH 7.0, 10% 
2-mercaptoethanol, 4% SDS, 20% glycerol, 0.05% 
Bromophenol  blue,  20  µl  1  mM  NaF,  1  mM  Na3VO4, 
and Complete Protease Inhibitor Cocktail Tablet (Roche, 
Nutley, NJ, USA) without EDTA and sonicated for 30 
seconds. Phospho-Akt was assayed with Phospho-Akt 
(Ser473) antibody (#9271, Cell Signaling Technology, 
Danvers, MA, USA). Subsequently the membrane was 
stripped and incubated with Akt1 (D-17) antibody (sc-
7126, Santa Cruz Biotechnology,Santa Cruz, CA, USA)) 
for loading control.
Intraspleenic tumor model
Intraspleenic-injected HCT116 liver and lung 
metastases in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
mice (Jackson Laboratory, Bar Harbor, ME, USA) were 
generated as described in Erikson et. al. [28]. J-series 
compounds were solubilized in 1:1 DMSO/Cremophor 
EL (Sigma-Aldrich) and diluted 2.3-fold in water to a final 
concentration of 7.5 mg/ml. 400 µl of this formulation (150 
mg/kg) was injected intraperitoneally (IP) once a day for 
three weeks, beginning the third day post-surgery. Mice 
were sacrificed after the treatment and the liver, lungs, 
and spleen sampled. DNA was extracted from organs 
with the DNeasy Blood & Tissue Kit (Qiagen). The qPCR 
assay used for quantification of human DNA in mouse 
organs has been described [34]. All mouse protocols were 
designed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and approved by the 
Institutional Animal Care and Use Committee.
Xenograft tumor model
Tumor xenografts were established by injecting 
5x106 HCT116 cells subcutaneously into the right flanks 
of female nude mice. Tumor volume was measured twice 
weekly using electronic calipers and calculated as length 
x width2 x 0.5. After tumors reached an average volume 
of 50 mm3, animals were treated daily with drugs at 150 
mg/kg via IP injection for three weeks. Tumor phospho-
Akt levels were determined following harvest on the last 
day of the study. Xenografts were excised, snap frozen in 
liquid nitrogen and pulverized with a pestle. Homogenized 
tissue was re-suspended in lysis buffer (Cell Signaling 
Technology) and protein contents normalized by Bradford 
assay (Bio-Rad Laboratories, Hercules, CA, USA). 
Western blots were performed as described above.
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